AstraZeneca's claim even after the Oxford vaccine's trials stop - this year the vaccine will come

Posted on 11th Sep 2020 by rohit kumar

A group of experts have started investigating the health of a Volunteer during clinical trials of the Covid-19 vaccine at Oxford University and AstraZeneca. Even though this development has slowed the speed of the vaccine, scientists are considering it as good.

 

However, the World Health Organization (WHO) has said that there is no need to get frustrated or disappointed by the incident. This happens in vaccine trials. Meanwhile, the Oxford Trial Serum Institute of India has stopped the ongoing vaccine in India.

 

100 volunteers have been vaccinated in India so far

 

The vaccine Kovyshield developed by Oxford University and AstraZeneca is running combined trials of Phase-2 and Phase-3 in India. The Doing Serum Institute of India has also stopped trials in India.

 

So far in India, 100 volunteers have been vaccinated under trials. It is planned to enroll 1,600 volunteers to complete the trial. Meanwhile, the Drug Regulator of India has sent a show-cause notice to the Serum Institute.

 

WHO said- it's no shock

 

WHO Chief Scientist Soumya Swaminathan in Geneva said the braking of the vaccine trials of Oxford and AstraZeneca is not a shock. This suggests that the process of vaccine manufacture is not always the same as "fast and straight road".

 

Swaminathan said it was good. We can also consider it a wake-up call. It is a lesson to all that research has its ups and downs. The same happens in clinical development. We have to be ready for that.

 

At the same time, the CEO of AstraZeneca has claimed that the volunteer who received the neurological problem was given the actual vaccine. Not dummy It is not yet understood whether the vaccine that causes the neurological disorder affecting the spine cod.

 

AstraZeneca CEO Pascal Soriot said that even after what happened, his vaccine could still be in the market by the end of this year. He assured the company's investors that this break was temporary. Soon the trials will gain momentum.

 

There will be trials of nasal spray vaccine in China

 

China has approved its first nasal spray vaccine for trials. The clinical trials of phase-1 will begin in November. In this, this nasal spray vaccine will be tried on 100 volunteers.

 

According to the report of the Chinese government newspaper Global Times, this nasal vaccine is a joint effort of Hong Kong and China. This includes researchers from the University of Hong Kong, Xiamen University, and Beijing Wantai Biological Pharmacy.

 

If the nasal spray vaccine contains influenza virus ie H1N1, H3N2, and B, it can give double protection against influenza and novel coronavirus. It may take a year to complete its trials.

 

Chinese company claims our vaccine safe

 

Meanwhile, the China National Biotech Group company said that no volunteers had any side-effects or adverse reactions even after two shots of its vaccine. Hundreds of people have been vaccinated so far.

 

The vaccine of China National Biotech Group Company, a subsidiary of Sinopharm Group Company, has been approved for emergency use in China. This vaccine has been introduced to the frontline workers even before the Phase-3 trials are completed.

 

Covid-19 Vaccine Update

 

180 vaccines are being made for COVID-19 worldwide.

The 35 vaccine is in the stage of clinical trials. That means their human trials are going on.

 

Phase-3 trials of 9 vaccines are underway. That is, it will remain in the last phase of all vaccine human trials.

 

These 9 vaccines include Oxford / AstraZeneca (UK), Moderna (US), Gamalaya (Russia), Janssen Pharma Companies (US), Sinopec (China), Wuhan Institute (China), Beijing Institute (China), Cancino Biologics (China). And Pfizer (US) vaccine.

 

145 vaccines are in the pre-clinical trials stage. That is, their testing is going on in labs.